TABLE VI.
Randomized controlled trials for primary prophylaxis in central venous catheters in cancer patients
| Trial | Patients (n) | Regimen | Duration of treatment | Outcome | Incidences | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Study | Control | vte | Major bleeding | ||||||||
| Study (%) | Control (%) | p Value | Study (%) | Control (%) | p Value | ||||||
| Couban et al., 2005 49 | 255 | Warfarin 1 mg | Placebo | Until dvt, or until line removed | cvc-associated thrombosis on ultrasound or venography | 4.6 | 4.0 | >0.05 | 0 | 2 | 0.5 |
| Young et al., 2005 50 | 1589 | Adjusted warfarin for inr 1.5–2.0 or warfarin 1 mg | Placebo | Until dvt, or until line removed | cvc-associated thrombosis on ultrasound or venography | 5 | 6 | 0.84 | 2 | 0.2 | 0.07 |
| Verso et al., 2005 51 | 321 | Enoxaparin 40 mg daily | Placebo | Until dvt, or until line removed | Venographic dvt, or pe | 14.1 | 18.0 | 0.35 | 0 | 0 | >0.05 |
| Karthaus et al., 2006 52 | 425 | Dalteparin 5000 IU daily | Placebo | 12 Weeks | pe, venographic or ultrasonographic dvt | 3.7 | 3.4 | 0.88 | 0.004 | 0 | >0.05 |
vte = venous thromboembolism; dvt = deep vein thrombosis; cvc = central venous catheter; inr = international normalized ratio; pe = pulmonary embolism.